Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide
DOI:
https://doi.org/10.2340/1651-226X.2024.40116Keywords:
Blood–brain barrier, perfusion, permeability, glioblastoma, anti-angiogenic treatment, DCE-MRI, Evans blueAbstract
Background and purpose: The poor delivery of drugs to infiltrating tumor cells contributes to therapeutic failure in glioblastoma. During the early phase of an anti-angiogenic treatment, a remodeling of the tumor vasculature could occur, leading to a more functional vessel network that could enhance drug delivery. However, the restructuration of blood vessels could increase the proportion of normal endothelial cells that could be a barrier for the free diffusion of drugs. The net balance, in favor or not, of a better delivery of compounds during the course of an antiangiogenic treatment remains to be established. This study explored whether cediranib and thalidomide could modulate perfusion and vessel permeability in the brain U87 tumor mouse model.
Methods: The dynamic evolution of the diffusion of agents outside the tumor core using the fluorescent dye Evans Blue in histology and Gd-DOTA using dynamic contrast-enhanced (DCE)-MRI. CD31 labelling of endothelial cells was used to measure the vascular density.
Results and interpretation: Cediranib and thalidomide effectively reduced tumor size over time. The accessibility of Evans Blue outside the tumor core continuously decreased over time. The vascular density was significantly decreased after treatment while the proportion of normal vessels remained unchanged over time. In contrast to histological studies, DCE-MRI did not tackle any significant change in hemodynamic parameters, in the core or margins of the tumor, whatever the parameter used or the pharmacokinetic model used. While cediranib and thalidomide were effective in decreasing the tumor size, they were ineffective in transiently increasing the delivery of agents in the core and the margins of the tumor.
Downloads
References
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
https://doi.org/10.1056/NEJMoa043330
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.
https://doi.org/10.1001/jama.2013.280319
Cha GD, Kang T, Baik S, Kim D, Choi SH, Hyeon T, et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J Control Release. 2020;328:350–67.
https://doi.org/10.1016/j.jconrel.2020.09.002
Gately L, McLachlan SA, Philip J, Ruben J, Dowling A. Long-term survivors of glioblastoma: a closer look. J Neurooncol. 2018;136:155–62.
https://doi.org/10.1007/s11060-017-2635-1
Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother. 2017;92:681–9.
https://doi.org/10.1016/j.biopha.2017.05.125
Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme – an overview. Contemp Oncol. 2014;18:307–12.
https://doi.org/10.5114/wo.2014.40559
Brighi C, Puttick S, Rose S, Whittaker AK. The potential for remodelling the tumour vasculature in glioblastoma. Adv Drug Deliv Rev. 2018;136–37:49–61.
https://doi.org/10.1016/j.addr.2018.10.001
Stylianopoulos T, Munn LL, Jain RK. Reengineering the tumor vasculature: improving drug delivery and efficacy. Trends Cancer. 2018;4:258–9.
Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584–96.
https://doi.org/10.1038/nm.3407
Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26–41.
https://doi.org/10.1038/s41568-019-0205-x
Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–78.
https://doi.org/10.1158/1078-0432.CCR-10-1564
Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, et al. Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases. Clin Cancer Res. 2016;22:6078–87.
https://doi.org/10.1158/1078-0432.CCR-16-1327
van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.
https://doi.org/10.1016/j.drup.2015.02.002
Gould A, Zhang D, Arrieta VA, Stupp R, Sonabend AM. Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas. Oncotarget. 2021;12:2474–5.
https://doi.org/10.18632/oncotarget.28018
Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L. Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors. Front Oncol. 2020;10:739.
https://doi.org/10.3389/fonc.2020.00739
Shen Y, Li S, Wang X, Wang M, Tian Q, Yang J, et al. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin. J Exp Clin Cancer Res. 2019;38:427.
https://doi.org/10.1186/s13046-019-1366-x
Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943–8.
https://doi.org/10.1158/0008-5472.CAN-12-4354
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071–21.
https://doi.org/10.1152/physrev.00038.2010
Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2016;7:21247–58.
https://doi.org/10.18632/oncotarget.6918
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
https://doi.org/10.1126/science.1104819
Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res. 2005;11:743–50.
https://doi.org/10.1158/1078-0432.743.11.2
Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205–18.
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27.
https://doi.org/10.1038/nrd3455
Magnussen AL, Mills IG. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer. 2021;125:324–36.
https://doi.org/10.1038/s41416-021-01330-z
Segers J, Di Fazio V, Ansiaux R, Martinive P, Feron O, Wallemacq P, et al. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature. Cancer Lett. 2006;244:129–35.
https://doi.org/10.1016/j.canlet.2005.12.017
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.
https://doi.org/10.1016/j.ccr.2006.11.021
Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72:402–7.
https://doi.org/10.1158/0008-5472.CAN-11-2464
Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016;113:4470–5.
https://doi.org/10.1073/pnas.1525349113
Ahishali B, Kaya M. Evaluation of blood-brain barrier integrity using vascular permeability markers: Evans blue, sodium fluorescein, albumin-alexa fluor conjugates, and horseradish peroxidase. Methods Mol Biol. 2021;2367:87–103.
https://doi.org/10.1007/7651_2020_316
Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, et al. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol. 2020;12:1758835920928635.
https://doi.org/10.1177/1758835920928635
Afshar Moghaddam N, Mahsuni P, Taheri D. Evaluation of endoglin as an angiogenesis marker in glioblastoma. Iran J Pathol. 2015;10:89–96.
Majchrzak K, Kaspera W, Szymaś J, Bobek-Billewicz B, Hebda A, Majchrzak H. Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas. Neurol Neurochir Pol. 2013;47:325–331.
https://doi.org/10.5114/ninp.2013.36757
Bianco J, Bastiancich C, Joudiou N, Gallez B, des Rieux A, Danhier F. Novel model of orthotopic U-87 MG glioblastoma resection in athymic nude mice. J Neurosci Methods. 2017;284:96–102.
Conq J, Joudiou N, Ucakar B, Vanvarenberg K, Préat V, Gallez B. Assessment of hyperosmolar blood-brain barrier opening in glioblastoma via histology with Evans blue and DCE-MRI. Biomedicines. 2023;11:1957. ttps://doi.org/10.3390/biomedicines11071957
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27:2542–52.
https://doi.org/10.1200/JCO.2008.19.9356
Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom AP, et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152–62.
https://doi.org/10.1016/j.brainres.2009.09.018
del Valle J, Camins A, Pallàs M, Vilaplana J, Pelegrí C. A new method for determining blood-brain barrier integrity based on intracardiac perfusion of an Evans Blue-Hoechst cocktail. J Neurosci Methods. 2008;174:42–9.
https://doi.org/10.1016/j.jneumeth.2008.06.025
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.
Sourbron SP, Buckley DL. Classic models for dynamic contrast-enhanced MRI. NMR Biomed. 2013;26:1004–27.
https://doi.org/10.1002/nbm.2940
Heye AK, Thrippleton MJ, Armitage PA, Valdés Hernández MDC, Makin SD, Glatz A, et al. Tracer kinetic modelling for DCE-MRI quantification of subtle blood-brain barrier permeability. Neuroimage. 2016;125:446–55.
https://doi.org/10.1016/j.neuroimage.2015.10.018
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
https://doi.org/10.1038/s41598-017-17204-5
Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol. 2019;56:6645–53.
https://doi.org/10.1007/s12035-019-1561-y
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol. 2023;41:1285–95.
https://doi.org/10.1200/JCO.22.00164
Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J, et al. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer. 2023;23:544.
https://doi.org/10.1186/s12885-023-11043-6
Begagić E, Pugonja R, Bečulić H, Čeliković A, Tandir Lihić L, Kadić Vukas S, et al. Molecular targeted therapies in glioblastoma multiforme: a systematic overview of global trends and findings. Brain Sci. 2023;13:1602.
https://doi.org/10.3390/brainsci13111602
Eatmann AI, Hamouda E, Hamouda H, Farouk HK, Jobran AWM, Omar AA, et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview. Metabolites. 2023;13:543.
https://doi.org/10.3390/metabo13040543
Wang Y, Xing D, Zhao M, Wang J, Yang Y. The Role of a Single angiogenesis inhibitor in the treatment of recurrent glioblastoma multiforme: a meta-analysis and systematic review. PLoS One. 2016;11:e0152170.
https://doi.org/10.1371/journal.pone.0152170
Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, et al. NRG/RTOG 0837: randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv. 2023;5:vdad116.
https://doi.org/10.1093/noajnl/vdad116
Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PØ, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 2012;14:979–93.
https://doi.org/10.1093/neuonc/nos135
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:813–23.
https://doi.org/10.1016/S1470-2045(21)00090-5
Wang M, Bergès R, Malfanti A, Préat V, Bastiancich C. Local delivery of doxorubicin prodrug via lipid nanocapsule–based hydrogel for the treatment of glioblastoma. Drug Deliv Transl Res. 2023. Online ahead of print.
https://doi.org/10.1007/s13346-023-01456-y
Conq J, Joudiou N, Preat V, Gallez B. Exploring the impact of irradiation on glioblastoma blood-brain-barrier permeability: insights from dynamic-contrast-enhanced-MRI and histological analysis. Biomedicines. 2024;12:1091.
https://doi.org/10.3390/biomedicines12051091
Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014;72:94–109.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Jérôme Conq, Nicolas Joudiou, Véronique Préat, Bernard Gallez
This work is licensed under a Creative Commons Attribution 4.0 International License.
